Razi Cem Hasan, Turktas Ipek, Bakirtas Arzu
Affiliations: Department of Pediatric Allergy and Asthma, Faculty of Medicine, Gazi University, Ankara, Turkey.
Ann Allergy Asthma Immunol. 2008 Apr;100(4):370-6. doi: 10.1016/s1081-1206(10)60601-1.
High repeated doses of inhaled corticosteroids (ICSs) are recognized as having a more rapid improvement of outcomes than a single dose of ICS in severe acute asthma. However, to our knowledge, there has been no direct comparison of the early effects of single or repeated administration of the same total dosage of ICS in children with moderate to severe exacerbations of asthma.
To compare the efficacy of a single dose of 2000 microg of nebulized budesonide with 4 repeated doses of 500 microg of nebulized budesonide in 40 children with an acute asthma exacerbation.
Randomized, double-blind, parallel study that compared the efficacy of 2000 microg of nebulized budesonide, administered in a single dose, with repeated doses (4 doses of 500 microg each) during the first 90 minutes in 40 children (mean [SD] age, 10.7 [2.4] years) with an acute asthma exacerbation that required treatment with an oral corticosteroid. Forced expiratory volume in 1 second, asthma attack score, and oxygen saturation were evaluated at 20, 40, 60, 90, 120, 180, and 240 minutes after initial treatment. Oral corticosteroids were given to all patients at 90 minutes.
There were no significant differences in forced expiratory volume in 1 second (P = .54) at any times between the groups. Also, asthma scores and oxygen saturation were not different in either group within 90 minutes (P = .51 and P = .64, respectively) and thereafter (P = .35 and P = .87, respectively).
The use of a single dose of nebulized budesonide is as effective as repeated administration of the same total dosage during the first 90 minutes before giving oral corticosteroids in children with moderate to severe exacerbations of asthma.
在重度急性哮喘中,高重复剂量吸入性糖皮质激素(ICSs)被认为比单剂量ICS能更快改善预后。然而,据我们所知,对于中度至重度哮喘加重期儿童,尚未对相同总剂量的ICS单剂量或重复给药的早期效果进行直接比较。
比较2000微克雾化布地奈德单剂量与4次重复剂量(每次500微克)雾化布地奈德对40例急性哮喘加重期儿童的疗效。
一项随机、双盲、平行研究,比较了40例(平均[标准差]年龄为10.7[2.4]岁)需要口服糖皮质激素治疗的急性哮喘加重期儿童,在最初90分钟内单剂量给予2000微克雾化布地奈德与重复剂量(每次500微克,共4次)的疗效。在初始治疗后20、40、60、90、120、180和240分钟评估第1秒用力呼气量、哮喘发作评分和血氧饱和度。所有患者在90分钟时给予口服糖皮质激素。
两组之间在任何时间的第1秒用力呼气量均无显著差异(P = 0.54)。此外,两组在90分钟内(分别为P = 0.51和P = 0.64)及之后(分别为P = 0.35和P = 0.87)的哮喘评分和血氧饱和度也无差异。
对于中度至重度哮喘加重期儿童,在给予口服糖皮质激素前的最初90分钟内,单剂量雾化布地奈德的使用与相同总剂量的重复给药效果相同。